This protocol describes how to slice and culture heart tissue under physiological conditions for 6 days. This culture system could be used as a platform for testing the efficacy of novel heart failure therapeutics as well as reliable testing of acute cardiotoxicity in a 3D heart model.
Many novel drugs fail in clinical studies due to cardiotoxic side effects as the currently available in vitro assays and in vivo animal models poorly predict human cardiac liabilities, posing a multi-billion-dollar burden on the pharmaceutical industry. Hence, there is a worldwide unmet medical need for better approaches to identify drug cardiotoxicity before undertaking costly and time consuming 'first in man' trials. Currently, only immature cardiac cells (human induced pluripotent stem cell-derived cardiomyocytes [hiPSC-CMs]) are used to test therapeutic efficiency and drug toxicity as they are the only human cardiac cells that can be cultured for prolonged periods required to test drug efficacy and toxicity. However, a single cell type cannot replicate the phenotype of the complex 3D heart tissue which is formed of multiple cell types. Importantly, the effect of drugs needs to be tested on adult cardiomyocytes, which have different characteristics and toxicity responses compared to immature hiPSC-CMs. Culturing human heart slices is a promising model of intact human myocardium. This technology provides access to a complete multicellular system that mimics the human heart tissue and reflects the physiological or pathological conditions of the human myocardium. Recently, through optimization of the culture media components and the culture conditions to include continuous electrical stimulation at 1.2 Hz and intermittent oxygenation of the culture medium, we developed a new culture system setup that preserves viability and functionality of human and pig heart slices for 6 days in culture. In the current protocol, we are detailing the method for slicing and culturing pig heart as an example. The same protocol is used to culture slices from human, dog, sheep, or cat hearts. This culture system has the potential to become a powerful predictive human in situ model for acute cardiotoxicity testing that closes the gap between preclinical and clinical testing results.
Drug induced cardiotoxicity is a major cause of market withdrawal1. In the last decade of the 20th century, eight non-cardiovascular drugs were withdrawn from the market as they resulted in sudden death due to ventricular arrhythmias2. In addition, several anti-cancer therapies (while in many cases effective) can lead to several cardiotoxic effects including cardiomyopathy and arrhythmias. For example, both traditional (e.g., anthracyclines and radiation) and targeted (e.g., trastuzumab) breast cancer therapies can result in cardiovascular complications in a subset of patients3. A close collaboration between cardiologists and oncologists (via the emerging field of "cardio-oncology") has helped make these complications manageable ensuring that patients can be treated effectively2. Less clear are the cardiovascular effects of newer agents, including Her2 and PI3K inhibitors, especially when therapies are used in combination. Therefore, there is a growing need for reliable preclinical screening strategies for cardiovascular toxicities associated with emerging anti-cancer therapies prior to human clinical trials. The lack of availability of culture systems for human heart tissue that is functionally and structurally viable for more than 24 h is a limiting factor for reliable cardiotoxicity testing. Therefore, there is an urgent need to develop a reliable system for culturing human heart tissue under physiologic conditions for testing drug toxicity.
The recent move towards the use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in cardiotoxicity testing has provided a partial solution to address this issue; however, the immature nature of the hiPSC-CMs and the loss of tissue integrity compared to multicellular nature of the heart tissue are major limitations of this technology4. A recent study has partially overcome this limitation through fabrication of cardiac tissues from hiPSC-CMs on hydrogels and subjecting them to gradual increase in electrical stimulation over time5. However, their electromechanical properties did not achieve the maturity seen in the adult human myocardium. Moreover, the heart tissue is structurally more complicated, being composed of various cell types including endothelial cells, neurons and various types of stromal fibroblasts linked together with a very specific mixture of extracellular matrix proteins6. This heterogeneity of the non-cardiomyocyte cell population7,8,9 in the adult mammalian heart is a major obstacle in modeling heart tissue using individual cell types. These major limitations highlight the importance of developing methods to enable culture of intact cardiac tissue for optimal studies involving physiological and pathological conditions of the heart5.
Culturing human heart slices is a promising model of intact human myocardium. This technology provides access to a complete 3D multicellular system that is similar to the human heart tissue which could reliably reflect the physiological or pathological conditions of the human myocardium. However, its use has been severely limited by the short period of viability in culture, which does not extend beyond 24 h using the most robust protocols reported until 201810,11,12. This limitation was due to multiple factors including the use of air-liquid interface to culture the slices, and the use of a simple culture medium that does not support the high energetic demands of the cardiac tissue. We have recently developed a submerged culture system which is able to provide continuous electrical stimulation and optimized the culture media components to keep cardiac tissue slices viable for up to 6 days13. This culture system has the potential to become a powerful predictive human in situ model for acute cardiotoxicity testing to close the gap between preclinical and clinical testing results. In the current article, we are detailing the protocol for slicing and culturing the heart slices using a pig heart as an example. The same process is applied to human, dog, sheep, or cat hearts. With this protocol, we are hoping to spread the technology to other laboratories in the scientific community.
All animal procedures were in accordance with the institutional guidelines of the University of Louisville and approved by the Institutional Animal Care and Use Committee.
1. Preparation for Slicing (One Day Before Slicing)
2. Pig Heart Perfusion
3. Pig Heart Tissue Slicing
4. Culturing Heart Slices
Using a commercially available cell culture electrical stimulator that can accommodate eight 6 well plates at once, we emulated the adult cardiac milieu by inducing electrical stimulation at the physiological frequency (1.2 Hz), and screened for the fundamental medium components to prolong the duration of functional pig heart slices in culture13. Since pig and human hearts are similar in size and anatomy15, we developed a biomimetic heart slice culture system using pig hearts and subsequently validated it in human heart slices. Here, we detailed the protocol for pig heart slices which is the same procedure for human heart slicing and culturing. The new biomimetic culture setup described here, maintained the viability of the pig heart slices for 6 days as assessed by MTT assay (Figure 1A). We confirmed the functional viability of these slices over 6 days by assessing their calcium homeostasis and contractile force. In the first 6 days, there is no spontaneous calcium transients in cardiomyocytes, and the cardiomyocytes responded to external electrical stimulation as well as β-adrenergic stimulation similar to fresh heart slices (Figure 1B). In addition, the contractile force and responses to isoproterenol are maintained in cultured heart slices for up to 6 days, similar to that of fresh heart slices (Figure 1C,D).
<!–
–>
Figure 1: Validation of the viability and functionality of pig heart slice culture. (A) Quantification of heart slice viability over time using the MTT assay in either stimulated or unstimulated culture system in optimized medium (n = 5 pig hearts each in triplicate, SEM is represented as error bars; two-way ANOVA test was conducted to compare between groups, *p < 0.05). (B) Representative calcium signal trace from a fresh heart slice (day 0) and after 6 days in culture (day 6) with and without 1 µM isoproterenol (Iso) stimulation. Transients were recorded after loading the heart slices with Fluo-4 calcium dye and using 1 Hz/20 V electrical stimulation at the time of recording. Quantification of calcium signal amplitude with and without stimulation with isoproterenol shows a similar pattern of calcium transients at day 0 and day 6 in culture (n = 4 pig hearts, 10−15 cells analyzed in each, SEM is represented as error bars; two-way ANOVA test was conducted to compare between groups, *p < 0.05 comparing baseline to Iso stimulation at the same time point, p-valueD0 vs D6 = 0.95, and p-valueD0 Iso vs D6 Iso = 0.93). (C) Contractile force assessment setup (left panel); the heart slice (HS) is hung between a force transducer (FT) and a stable post (P) between two electric electrodes (EE) for electrical stimulation. Upon stimulation, the slice contracts and the contractions are recorded using the designated software (right panel). (D) Bar graph shows the quantification of the contractile force in the presence or absence of isoproterenol (Iso) generated by fresh pig heart slices (day 0) and after 6 days in biomimetic culture (n = 4 pig hearts each in triplicate, SEM is represented as error bars; two-way ANOVA test was conducted to compare between groups, *p < 0.05 comparing baseline to Iso stimulation at the same time point, twitch force: p-valueD0 vs D6 = 0.96, p-valueD0 Iso vs D6 Iso = 0.81; time to 50% relaxation: p-valueD0 vs D6 = 0.47, p-valueD0 Iso vs D6 Iso = 0.43). This figure has been modified from Ou et al.13. Please click here to view a larger version of this figure.
Condition | Fischer et al.16 | Ou et al.13 |
Species | Human | Pig and human |
Disease | Failing hearts | Normal healthy hearts |
Preservation | Preserved tissue | Fresh tissue |
Slice thickness | 300 µm | 300 µm |
Medium Oxygenation | No | Intermittant oxygenation |
Culture Medium | M199/ITS | M199/ITS/FBS/VEGF/FGF |
Agitation | Yes | No |
Pacing rate | 0.2 Hz | 1.2 Hz |
Duration of the culture | 4 months with compromise | 6 days with no compromise |
Cuture Temperature | 37 | 37 |
Mechanical loading | auxotonic loading | no loading |
Tested time points with no change in gene expression compared to fresh heart slice | N/A | 2 and 6 days |
First tested time point to show change in gene expression | Day 8 | Day 10 |
Table 1: Comparison between the slicing and culturing conditions used in Fischer et al.16 and Ou et al.13.
Here we describe the detailed video protocol for our recently published method for simplified medium throughput (processes up to 48 slices/device) method that enables culture of pig heart slices for a period sufficiently long to test acute cardiotoxicity13. The proposed conditions mimic the environment of the heart, including frequency of electrical stimulation, nutrient availability, and intermittent oxygenation. We attribute the prolonged viability of heart slices in our biomimetic stimulated culture to our focus on recreating the physiological conditions experienced by the intact heart. This concept is supported by our data showing that electrical stimulation alone, without providing essential nutrients, is not sufficient to maintain heart slice viability13. Therefore, the new components of the culture medium are the major driver for prolonging the heart slice viability and functionality in culture. We found that it is essential to include FBS in the medium to maintain the viability, which is likely due to the requirement for a variety of fatty acids, trace elements, enzymes, proteins, macromolecules, chemical components, and hormones, which are usually present in the serum and delivered to heart tissue in vivo17. Furthermore, we found that the addition of FGF and VEGF to the culture medium are needed to enhance the tissue viability. FGF and VEGF are known angiogenic factors which are essential for maintenance of cultured endothelial cells18. Therefore, it is likely that FGF and VEGF are needed to maintain the endothelial cells and connective tissues in culture to support tissue viability. Our work is the first to modify the simplified culture medium previously reported for culturing heart slices, and it opens the possibility for further optimization of the media components in subsequent studies.
In a timely manner with our new method, there were three other studies that have demonstrated the importance of continuous electromechanical stimulation in maintaining slices in culture in bioengineered systems16,19,20. However, these studies used the basal M199/ITS medium, which is not sufficient to maintain the metabolic needs of heart slices. This led to several compromises in the slice contractility and calcium homeostasis early during culture16,19,20. Qiao et al.19 developed a highly sophisticated bioengineered chips, which can maintain the electrophysiological properties of the heart slices for 4 days, but no assessment of the contractile function was provided. Watson et al.20 have bioengineered a low throughput culture system (processes up to 4 slices/device) to demonstrate the importance of diastolic sarcomere length for the maintenance of cardiac muscle properties for 24 h. Finally, Fischer et al.16 have shown that failing human heart slices can be maintained in vitro for up to 4 months when cultured under 0.2 Hz stimulation, auxotonic loading and media agitation in a bioengineering device. However, these conditions induced a variety of changes in the heart slices, as reflected in their RNAseq data, which showed over 10 fold downregulation of cardiac gene expression as early as the first time point of assessment (day 8)16. However, in our optimized culture system, only 2 and 5 transcripts were significantly differentially expressed after 2 and 6 days in culture compared to fresh heart tissue, respectively. However, after 10 days in culture, there were significant changes in the expression of over 500 transcripts. The downregulated genes after 10 days in culture were mostly related to cardiac muscle, while the upregulated genes are related to fibroblasts, extracellular matrix, and inflammation13. Table 1 includes a full comparison of slicing and culture protocols between Fischer et al.16 and Ou et al.13. Therefore, our biomimetic stimulated culture system emulates the controllable conditions experienced by the heart in situ and, therefore, should provide a reliable readout of the functional and the structural outcomes of drug treatment with regard to acute cardiotoxicity or efficacy compared to compromised culture systems.
One of the major limitations of this culture system is that although our culture system can emulate several physiological conditions, it cannot mimic changes in mechanical load and shear stress during the cardiac contractile cycle. Further optimization of physiological and metabolic factors could help prolong heart slice viability and function. Additionally, we noticed an early adaptation which leads to diminishment of oxidative phosphorylation which might instigate deterioration of the heart slice viability13. Unfortunately, so far, we were not able to identify an optimal method to maintain oxidative phosphorylation. It is likely that enhancing fatty acid metabolism in heart slices is not as simple as adding fatty acids to the growth medium, and will require further optimization, which could be addressed in future studies. Furthermore, a general weakness of this approach is the missing measurement of action potentials on single cardiomyocytes within the heart slice, which is essential to demonstrate disruption in electrocardiogram and ventricular arrhythmia. Therefore, there is a need to optimize protocols to isolate single cardiomyocytes from the heart slices after treatment with cardiotoxins that induce disruption in electrocardiogram and assess their effect on the action potential on the isolated cardiomyocytes.
The authors have nothing to disclose.
TMAM is supported by NIH grant P30GM127607 and American Heart Association grant 16SDG29950012. RB is supported by P01HL78825 and UM1HL113530.
1000ml, 0.22µm, Vacuum Filter/Storage Systems | VWR | 28199-812 | |
2,3-Butanedione monoxime (BDM) | Fisher | AC150375000 | |
500ml, 0.22µm, Vacuum Filter/Storage Systems | VWR | 28199-788 | |
6-well C-Dish Cover (electrical-stimulation-plate-cover) | Ion Optix | CLD6WFC | |
6-well plates | Fisher | 08-772-1B | |
Agarose | Bioline USA | BIO-41025 | |
Antibiotic-Antimycotic | Thermo | 15-240-062 | |
C-Pace EM (cell-culture-electrical-stimulator) | Ion Optix | CEP100 | |
Calcium Chloride (CaCl2) | Fisher | C79-500 | |
Ceramic Blades for Vibrating Microtome | Campden Instruments | 7550-1-C | |
Cooley Chest Retractor | Millennium Surgical | 63-G5623 | |
D-Glucose | Fisher | D16-1 | |
Disposable Scalpel #20 | Biologyproducts.com | DS20X | |
Falcon Cell Strainers, Sterile, Corning | VWR | 21008-952 | |
Fetal Bovine Serum | Thermo | A3160502 | |
Graefe Forceps | Fisher | NC9475675 | |
Heparin sodium salt | Sigma-Aldrich | H3149-50KU | |
HEPES | Fisher | BP310-1 | |
Histoacryl BLUE Tissue glue | Amazon | https://www.amazon.com/HISTOACRYL-FLEXIBLE-1051260P-Aesculap-Adhesive/dp/B074WB5185/ | |
Iris Spring scissors | Fisher | NC9019530 | |
Iris Straight Scissors | Fisher | 731210 | |
Isoflurane, USP | Piramal | NDC 66794-017-25 | |
ITS Liquid Media Supplement | Sigma-Aldrich | I3146-5ML | |
Ketamine HCl (500 mg/10 mL) | West-Ward | NDC 0143-9508 | |
Magnesium Chloride (MgCl2) | Fisher | M33-500 | |
Mayo SuperCut Surgical Scissors | AROSurgical Instruments Corporation | AROSuperCut™ 07.164.17 | |
Medium 199, Earle's Salts | Thermo | 11-150-059 | |
Oxygen regulator | Praxair | ||
Oxygen tanks – | Praxair | ||
Plastic Pasteur pipettes | Fisher | 13-711-48 | |
Potassium Chloride (KCl) | Fisher | AC193780010 | |
Printer Timing Belt | Amazon | https://www.amazon.com/Uxcell-a14081200ux0042-PRINTER-Precision-Timing/dp/B00R1J3KDC/ | |
Razor rectangle blades | Fisher | 12-640 | |
Recombinant Human FGF basic | R&D Systems | 233-FB-025/CF | |
Recombinant Human VEGF | R&D Systems | 293-VE-010/CF | |
Retractable scalpels | Fisher | 22-079-716 | |
Sodium Bicarbonate (NaHCO3) | Fisher | AC217125000 | |
Sodium Chloride (NaCl) | Fisher | AC327300010 | |
Vibrating Microtome | Campden Instruments | 7000 SMZ-2 | |
Xylazine HCl (100 mg/mL) | Heartland Veterinary Supply | NADA 139-236 |